Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-01-30FDA Approved: LAMOTRIGINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approves Alembic Pharmaceuticals Limited's supplemental application for a lamotrigine chewable dispersible formulation, adding this dosa…
-
FDA approval · 2026-01-30FDA Approved: BRIVARACETAM — Supplemental Application (SolarisPharmaCorporation)
The FDA approved a supplemental application for brivaracetam from SolarisPharmaCorporation, signaling regulatory action to update the drug's…
-
FDA approval · 2026-01-29FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
FDA granted a supplemental approval for gabapentin submitted by Actavis Pharma, Inc. The action represents a supplemental regulatory action …
-
FDA approval · 2026-01-29FDA Approved: LACOSAMIDE ORAL SOLUTION — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved the original application for Lacosamide Oral Solution from Florida Pharmaceutical Products, LLC, adding a generic formulation f…
-
FDA approval · 2026-01-29FDA Approved: GABAPENTIN — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Gabapentin from Rising Pharma Holdings, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-01-28FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for divalproex sodium submitted by BluePoint Laboratories.
-
EMA approval · 2026-01-27EMA Authorised: Briviact (in Italy: Nubriveo) (Brivaracetam) — UCB Pharma SA
The EMA lists Briviact (brivaracetam) as authorised in Italy under the brand Nubriveo for epilepsy, with UCB Pharma SA as the marketing auth…
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam Actavis (levetiracetam) — Actavis Group PTC ehf
The European Medicines Agency has authorised Levetiracetam Actavis, a generic levetiracetam product, for use in epilepsy.
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam Teva (levetiracetam) — Teva B.V.
EMA has authorised Levetiracetam Teva (levetiracetam) for the treatment of epilepsy. The marketing authorization holder is Teva B.V., with d…
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam ratiopharm (levetiracetam) — ratiopharm GmbH
The EMA has authorised a generic levetiracetam product (Levetiracetam ratiopharm) by ratiopharm GmbH for epilepsy.
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam Actavis Group (levetiracetam) — Actavis Group PTC ehf
EU marketing authorisation granted for Actavis Group PTC ehf's generic levetiracetam for epilepsy.
-
EMA approval · 2026-01-21EMA Authorised: Lacosamide Adroiq (lacosamide) — Extrovis EU Ltd
The European Medicines Agency authorised Lacosamide Adroiq for the treatment of epilepsy, with Extrovis EU Ltd as the marketing authorizatio…
-
FDA approval · 2026-01-21FDA Approved: LACOSAMIDE — Original Application (GLENMARK PHARMACEUTICALS INC., USA)
FDA approved Glenmark Pharmaceuticals' lacosamide original application, authorizing a generic lacosamide product. Lacosamide is used for the…
-
FDA approval · 2026-01-18FDA Approved: TOPIRAMATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves a supplemental application for TOPIRAMATE from Glenmark Pharmaceuticals Inc., USA.
-
FDA approval · 2026-01-14FDA Approved: GABAPENTIN — Supplemental Application (Laurus Labs Limited)
FDA approved a supplemental application for gabapentin from Laurus Labs Limited (ANDA217965). This action approves the generic product for d…
-
FDA approval · 2026-01-12FDA Approved: TOPIRAMATE — Original Application (Camber Pharmaceuticals, Inc.)
This FDA page confirms Camber Pharmaceuticals' original Abbreviated New Drug Application approval for a generic Topiramate product. The appr…
-
FDA approval · 2026-01-08FDA Approved: LAMOTRIGINE — Original Application (Torrent Pharmaceuticals Limited)
FDA approved an original ANDA for lamotrigine from Torrent Pharmaceuticals Limited, authorizing a generic lamotrigine product for use in app…
-
FDA approval · 2026-01-08FDA Approved: ACETAZOLAMIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for acetazolamide from Strides Pharma Science Limited. The document indicates approval of a suppleme…
-
EMA approval · 2026-01-05EMA Authorised: Levetiracetam Sun (levetiracetam) — Sun Pharmaceutical Industries Europe B.V.
The EMA has authorised Levetiracetam Sun, a generic levetiracetam product by Sun Pharmaceutical Industries Europe B.V., for epilepsy.
-
FDA approval · 2025-12-31FDA Approved: LAMOTRIGINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Lamotrigine from Aurobindo Pharma Limited, authorizing the marketing of a generic Lamotrigine pr…
-
EMA approval · 2025-12-19EMA Authorised: Pregabalin Viatris (previously Pregabalin Mylan) (pregabalin) — Viatris Limited
The EMA authorised Pregabalin Viatris for anxiety disorders and epilepsy, with Viatris Limited as the marketing authorisation holder.
-
EMA approval · 2025-12-16EMA Authorised: Matever (levetiracetam) — Pharmathen S.A.
The EMA authorised Matever (levetiracetam) by Pharmathen S.A. for the treatment of epilepsy. Decision date: 16 December 2025.
-
EMA approval · 2025-12-15EMA Authorised: Levetiracetam Hospira (levetiracetam) — Pfizer Europe MA EEIG
The EMA has granted marketing authorization for Levetiracetam Hospira (levetiracetam) as a generic anti-epileptic drug for epilepsy, with Pf…
-
EMA approval · 2025-12-09EMA Authorised: Levetiracetam Accord (levetiracetam) — Accord Healthcare S.L.U.
The EMA authorised Levetiracetam Accord for epilepsy, granting EU marketing authorization to Accord Healthcare S.L.U.
-
FDA approval · 2025-12-04FDA Approved: TOPIRAMATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark Pharmaceuticals' supplemental application for Topiramate, enabling a generic version of this anticonvulsant. The a…